



Company Announcement no. 9/2014

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 25 marts 2014

Warrant Programme - New Articles of Association

In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 14 March 2014 issued 22,967,756 warrants for the subscription of nominally DKK 22,967,756 shares in the Company.

The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association are for Veloxis Pharmaceuticals A/S are attached.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino
President & CEO
Mobile: +1 917 647 9107
Email: wjp@veloxis.com

Johnny Stilou
EVP, Chief Financial Officer
Mobile: +45 21 227 227
Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.